Alkermes plc(ALKS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | RUT | P/E | 115.12 | EPS (ttm) | 0.39 | Insider Own | 2.98% | Shs Outstand | 167.5M | Perf Week | 0.48% |
| Market Cap | 7.44B | Forward P/E | 81.29 | EPS next Y | 200.58% | Insider Trans | -2.49% | Shs Float | 162.8M | Perf Month | 10.39% |
| Enterprise Value | 8.35B | PEG | - | EPS next Q | -0.08 | Inst Own | 105.36% | Short Float | 11.7% | Perf Quarter | -8.32% |
| Income | 0.07B | P/S | 4.46 | EPS this Y | -137.9% | Inst Trans | -0.71% | Short Ratio | 9.95 | Perf Half Y | 29.82% |
| Sales | 1.67B | P/B | 4.11 | EPS next 5Y | -11.16% | ROA | 1.99% | Short Interest | 19.05M | Perf YTD | 58.4% |
| Book/sh | 10.79 | P/C | 11.32 | EPS past 3/5Y | - | ROE | 3.85% | 52W High | -20.39% ($55.67) | Perf Year | 49.13% |
| Cash/sh | 3.91 | P/FCF | 33.55 | Sales past 3/5Y | 9.9% 7.28% | ROIC | 1.98% | 52W Low | 64.15% ($27.00) | Perf 3Y | 99.48% |
| Dividend Est. | - | EV/EBITDA | 40.68 | EPS Y/Y TTM | -81.14% | Gross Margin | 82.13% | Volatility(W/M) | 2.81% 3.35% | Perf 5Y | 66.41% |
| Dividend TTM | - | EV/Sales | 5.01 | Sales Y/Y TTM | 10.79% | Oper. Margin | 8.62% | ATR (14) | 1.45 | Perf 10Y | -7.82% |
| Dividend Ex-Date | - | Quick Ratio | 1.85 | EPS Q/Q | -99.44% | Profit Margin | 3.97% | RSI (14) | 57.12 | Recom | 1.63 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.3 | Sales Q/Q | 26.97% | SMA20 | 5.91% ($41.85) | Beta | 0.34 | Target Price | $56.37 |
| Payout | - | Debt/Eq | 0.87 | Earnings | 2026/11/3 | SMA50 | 0.07% ($44.29) | Rel Volume | 0.69 | Prev Close | $44.44 |
| Employees | 2050 | LT Debt/Eq | 0.85 | EPS/Sales Surpr. | 100% 8.45% | SMA200 | 10.13% ($40.24) | Avg Volume(3M) | 1.91M | Price | $44.32 |
| IPO | 1991/7/16 | Option/Short | Yes/Yes | Trades | 10723 | Volume | 1,322,006 | Change | -0.27% |
🧠 This is a commercial-stage biopharmaceutical company that develops and sells treatments for central nervous system (CNS) disorders. It generates revenue and profit by selling therapies for neurological and psychiatric conditions such as schizophrenia, bipolar disorder, and addiction, while also advancing a pipeline that includes treatments for narcolepsy and other indications, making it a healthcare stock whose performance is tied to both its revenue base and pipeline progress.
Over the past 1 year, roughly in the middle
20% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
Next earnings report: November 3
6 days to go.
ALKS earns at a steady pace
Of every $100 in sales, $8.62 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -137.9% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $11,512. Peers typically go for $2,112. Compared with its own 3-year average, it is 646% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +66.4%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 105.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #10 of 83 in the industry
Based on market cap of $7B.
Earnings Analysis · 7/28 Alkermes ($ALKS) Q2 2026 Earnings Analysis — Revenue Beats Estimates at $496M; First Full Quarter of Lumryz Contribution; Full-Year Adjusted Earnings Outlook Maintained Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners FAQ
What kind of company is ALKS?
ALKS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ALKS?
The market cap of ALKS is approximately $7.4B, ranking 1,089 within its sector.
What is the P/E ratio of ALKS?
ALKS has a P/E ratio of approximately 115.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ALKS?
ALKS has recorded a 52-week high of $55.67 and a low of $27.00.
